Cargando…
A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327727/ https://www.ncbi.nlm.nih.gov/pubmed/33792222 http://dx.doi.org/10.3324/haematol.2021.278301 |
| _version_ | 1783732154771963904 |
|---|---|
| author | Kim, Miso Lee, Jeong-Ok Koh, Jiwon Kim, Tae Min Lee, Ji Yun Jeon, Yoon Kyung Keam, Bhumsuk Kim, Dong-Wan Lee, Jong Seok Heo, Dae Seog |
| author_facet | Kim, Miso Lee, Jeong-Ok Koh, Jiwon Kim, Tae Min Lee, Ji Yun Jeon, Yoon Kyung Keam, Bhumsuk Kim, Dong-Wan Lee, Jong Seok Heo, Dae Seog |
| author_sort | Kim, Miso |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8327727 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83277272021-08-11 A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas Kim, Miso Lee, Jeong-Ok Koh, Jiwon Kim, Tae Min Lee, Ji Yun Jeon, Yoon Kyung Keam, Bhumsuk Kim, Dong-Wan Lee, Jong Seok Heo, Dae Seog Haematologica Letters to the Editor Fondazione Ferrata Storti 2021-04-01 /pmc/articles/PMC8327727/ /pubmed/33792222 http://dx.doi.org/10.3324/haematol.2021.278301 Text en Copyright© 2021 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letters to the Editor Kim, Miso Lee, Jeong-Ok Koh, Jiwon Kim, Tae Min Lee, Ji Yun Jeon, Yoon Kyung Keam, Bhumsuk Kim, Dong-Wan Lee, Jong Seok Heo, Dae Seog A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas |
| title | A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas |
| title_full | A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas |
| title_fullStr | A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas |
| title_full_unstemmed | A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas |
| title_short | A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas |
| title_sort | phase ii study of brentuximab vedotin in patients with relapsed or refractory epstein-barr virus-positive and cd30-positive lymphomas |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327727/ https://www.ncbi.nlm.nih.gov/pubmed/33792222 http://dx.doi.org/10.3324/haematol.2021.278301 |
| work_keys_str_mv | AT kimmiso aphaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT leejeongok aphaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT kohjiwon aphaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT kimtaemin aphaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT leejiyun aphaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT jeonyoonkyung aphaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT keambhumsuk aphaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT kimdongwan aphaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT leejongseok aphaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT heodaeseog aphaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT kimmiso phaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT leejeongok phaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT kohjiwon phaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT kimtaemin phaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT leejiyun phaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT jeonyoonkyung phaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT keambhumsuk phaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT kimdongwan phaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT leejongseok phaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas AT heodaeseog phaseiistudyofbrentuximabvedotininpatientswithrelapsedorrefractoryepsteinbarrviruspositiveandcd30positivelymphomas |